> Detailanzeige

Bollman, Brooke; Nunna, Naveen; Bahl, Kapil; Hsiao, Chiaowen Joyce; Bennett, Hamilton; Butler, Scott; Foreman, Bryant; Burgomaster, Katherine E.; Aleshnick, Maya; Kong, Wing-Pui; Fisher, Brian E.; Ruckwardt, Tracy J.; Morabito, Kaitlyn M.; Graham, Barney S.; Dowd, Kimberly A.; Pierson, Theodore C.; Carfi, Andrea

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection
  • Beteiligte: Bollman, Brooke; Nunna, Naveen; Bahl, Kapil; Hsiao, Chiaowen Joyce; Bennett, Hamilton; Butler, Scott; Foreman, Bryant; Burgomaster, Katherine E.; Aleshnick, Maya; Kong, Wing-Pui; Fisher, Brian E.; Ruckwardt, Tracy J.; Morabito, Kaitlyn M.; Graham, Barney S.; Dowd, Kimberly A.; Pierson, Theodore C.; Carfi, Andrea
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: npj Vaccines, 8 (2023) 1
  • Sprache: Englisch
  • DOI: 10.1038/s41541-023-00656-4
  • ISSN: 2059-0105
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractZika virus (ZIKV), an arbovirus transmitted by mosquitoes, was identified as a cause of congenital disease during a major outbreak in the Americas in 2016. Vaccine design strategies relied on limited available isolate sequence information due to the rapid response necessary. The first-generation ZIKV mRNA vaccine, mRNA-1325, was initially generated and, as additional strain sequences became available, a second mRNA vaccine, mRNA-1893, was developed. Herein, we compared the immune responses following mRNA-1325 and mRNA-1893 vaccination and reported that mRNA-1893 generated comparable neutralizing antibody titers to mRNA-1325 at 1/20th of the dose and provided complete protection from ZIKV challenge in non-human primates. In-depth characterization of these vaccines indicated that the observed immunologic differences could be attributed to a single amino acid residue difference that compromised mRNA-1325 virus-like particle formation.
  • Zugangsstatus: Freier Zugang